West Pharmaceutical Services, Inc. $WST is Seilern Investment Management Ltd’s 7th Largest Position

Seilern Investment Management Ltd decreased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 38.8% during the second quarter, Holdings Channel.com reports. The institutional investor owned 138,230 shares of the medical instruments supplier’s stock after selling 87,791 shares during the quarter. West Pharmaceutical Services accounts for about 6.3% of Seilern Investment Management Ltd’s portfolio, making the stock its 7th largest position. Seilern Investment Management Ltd’s holdings in West Pharmaceutical Services were worth $49,625,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Brendel Financial Advisors LLC bought a new position in West Pharmaceutical Services in the fourth quarter valued at $3,742,000. Bank of Nova Scotia lifted its stake in West Pharmaceutical Services by 337.8% during the first quarter. Bank of Nova Scotia now owns 65,323 shares of the medical instruments supplier’s stock worth $16,373,000 after purchasing an additional 50,402 shares during the last quarter. Birch Hill Investment Advisors LLC boosted its holdings in shares of West Pharmaceutical Services by 11.5% in the 4th quarter. Birch Hill Investment Advisors LLC now owns 152,148 shares of the medical instruments supplier’s stock worth $41,862,000 after purchasing an additional 15,678 shares in the last quarter. Annex Advisory Services LLC boosted its holdings in shares of West Pharmaceutical Services by 8.7% in the 4th quarter. Annex Advisory Services LLC now owns 122,958 shares of the medical instruments supplier’s stock worth $33,831,000 after purchasing an additional 9,800 shares in the last quarter. Finally, Hsbc Holdings PLC increased its position in shares of West Pharmaceutical Services by 23.3% during the 4th quarter. Hsbc Holdings PLC now owns 146,872 shares of the medical instruments supplier’s stock valued at $40,425,000 after purchasing an additional 27,745 shares during the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Trading Up 1.4%

NYSE WST opened at $353.61 on Friday. The firm has a market cap of $24.89 billion, a PE ratio of 45.28, a price-to-earnings-growth ratio of 2.47 and a beta of 1.15. West Pharmaceutical Services, Inc. has a 1-year low of $223.83 and a 1-year high of $386.00. The stock has a 50-day moving average of $342.97 and a 200-day moving average of $292.25. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.08 by $0.29. The business had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.West Pharmaceutical Services’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same period last year, the company earned $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, sell-side analysts forecast that West Pharmaceutical Services, Inc. will post 8.94 EPS for the current year.

West Pharmaceutical Services Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were issued a $0.22 dividend. The ex-dividend date was Wednesday, July 29th. This represents a $0.88 annualized dividend and a dividend yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 11.27%.

Analysts Set New Price Targets

A number of research firms recently weighed in on WST. Citigroup boosted their target price on West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Stephens reiterated an “overweight” rating and set a $360.00 price target on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of West Pharmaceutical Services in a research note on Friday, July 24th. Zacks Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Finally, TD Cowen reaffirmed a “buy” rating on shares of West Pharmaceutical Services in a report on Wednesday, July 15th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, West Pharmaceutical Services has a consensus rating of “Buy” and a consensus target price of $368.08.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.